- Home
- ATNM vs DTIL Comparison
ATNM vs DTIL Comparison
Compare ATNM & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- DTIL
- Stock Information
- Founded
- ATNM 2000
- DTIL 2006
- Country
- ATNM United States
- DTIL United States
- Employees
- ATNM N/A
- DTIL N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- ATNM Health Care
- DTIL Health Care
- Exchange
- ATNM Nasdaq
- DTIL Nasdaq
- Market Cap
- ATNM 51.5M
- DTIL 51.6M
- IPO Year
- ATNM N/A
- DTIL 2019
- Fundamental
- Price
- ATNM $1.52
- DTIL $4.79
- Analyst Decision
- ATNM Strong Buy
- DTIL Strong Buy
- Analyst Count
- ATNM 3
- DTIL 2
- Target Price
- ATNM $4.67
- DTIL $47.00
- AVG Volume (30 Days)
- ATNM 246.6K
- DTIL 85.2K
- Earning Date
- ATNM 08-04-2025
- DTIL 07-31-2025
- Dividend Yield
- ATNM N/A
- DTIL N/A
- EPS Growth
- ATNM N/A
- DTIL N/A
- EPS
- ATNM N/A
- DTIL N/A
- Revenue
- ATNM N/A
- DTIL $51,141,000.00
- Revenue This Year
- ATNM N/A
- DTIL N/A
- Revenue Next Year
- ATNM N/A
- DTIL $30.20
- P/E Ratio
- ATNM N/A
- DTIL N/A
- Revenue Growth
- ATNM N/A
- DTIL N/A
- 52 Week Low
- ATNM $1.03
- DTIL $3.61
- 52 Week High
- ATNM $8.64
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- ATNM 42.39
- DTIL 44.86
- Support Level
- ATNM $1.41
- DTIL $4.20
- Resistance Level
- ATNM $1.95
- DTIL $5.29
- Average True Range (ATR)
- ATNM 0.13
- DTIL 0.36
- MACD
- ATNM -0.04
- DTIL -0.03
- Stochastic Oscillator
- ATNM 6.54
- DTIL 36.88
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.